Advertisement

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Rosemary E. Gale, Teodora Popa, Melissa Wright, Naeem Khan, Sylvie D. Freeman, Alan K. Burnett, Nigel H. Russell, Robert K. Hills and David C. Linch

Article Information

PubMed 

Print ISSN 
Online ISSN 


Contributors 
  • Rosemary E. Gale, 1 Department of Haematology, University College London Cancer Institute, United Kingdom;
  • Teodora Popa, 1 Department of Haematology, University College London Cancer Institute, United Kingdom;
  • Melissa Wright, 2 Centre for Trials Research, Cardiff University, United Kingdom;
  • Naeem Khan, 3 Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom;
  • Sylvie D. Freeman, 3 Department of Clinical Immunology, Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom;
  • Alan K. Burnett, 4 Department of Haematology, Cardiff University School of Medicine, United Kingdom;
  • Nigel H. Russell, 5 Department of Haematology, Nottingham University Hospital NHS Trust, United Kingdom
  • Robert K. Hills, 2 Centre for Trials Research, Cardiff University, United Kingdom;
  • David C. Linch, 1 Department of Haematology, University College London Cancer Institute, United Kingdom;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output